Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula
- Buyer
- BARDA - ASPR / DAAPPO / BARDA DCMA
- Country
- United States
- Value
- 213.9m USD
- Published
- 2026-09-25
- Type
- Award Notice
- Status
- Awarded / closed
Get new Other tenders in United States by email
One free weekly email with the newest matching notices, each with at least a few days left to respond. No account, unsubscribe in one click.
Other open Other tenders in United States
About this record
This notice was published via SAM.gov and indexed automatically. Figures and dates are reproduced as published at source; always confirm against the original before acting on a deadline.